Fig. 1 · Structure
Documents & Downloads
Brentuximab vedotin (solution)
ADC
Brentuximab vedotin (solution) is an antibody-drug conjugate (ADC) that combines an anti-CD30 antibody with the cytotoxic agent Monomethyl auristatin E (MMAE) via a VcMMAE linker. This compound selectively targets CD30-positive cells, exhibiting potent inhibitory activity with an IC50 value of 2.5 ng/mL. Brentuximab vedotin (solution) is primarily utilized in research focused on relapsed and refractory Hodgkin lymphoma, making it valuable for studies on targeted cancer therapies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 914088-09-8 |
| Applications | ADC |
| Molecular Weight | 153000 (average) |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.